Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote

This article was originally published in RPM Report

Executive Summary

Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.

Advertisement

Related Content

“Do Not Compound” List One Step Closer, After FDA Names Advisors
Mystery Adcomm Revealed
Animal Rule Studies Should Be As Well-Designed As Human Clinical Trials, Panel Says
Conflict Over Conflicts: FDA Advisory Committee Rules May Be Ripe For Change
FDA “Flexibility” Presages Good Climate in 2012 for Approval Decisions, Shortage Situations
Collaring Wolfe: Propoxyphene Moves Activist Back To Public Supplicant Role
A Seat At The Drug Safety Table: Public Citizen’s Wolfe Joins FDA Advisory Committee
FDA Advisory Committees on the Brink: More Meetings, Fewer Members
The Role Of RiskMAPs: Fentora Shows Shift From Post-Market To Pre-Market
Panel Abuses Purdue Over OxyContin

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS081013

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel